Who
Anthony James Culverwell
Director
Company insider
Files Form 4 as: Director, Quoin Pharmaceuticals; Director, Innocoll Holdings.
In numbers
- Trades disclosed
- 20
- Buys
- 2
- Sells
- 0
- Bought
- $105K
- Sold
- $0
- Companies
- 2
- Companies where not an officer
- 2
- First trade
- 24 Jul 2017
- Last trade
- 31 Aug 2026
- Last filed
- 1 Sep 2026
Companies traded
Activity over time
1 Dec 2024 – 1 Oct 2026
Buys above the line, sells below, each month.
Every trade
| Traded | Company | What | Amount | |
|---|---|---|---|---|
| 31 Aug 2026filed 1 Sep 2026 | QNRX Quoin PharmaceuticalsBiotechnology | SEC FORM 4 Bought | $30K6,146 at $4.88 | filing |
| 31 Aug 2026filed 1 Sep 2026 | QNRX Quoin Pharmaceuticalsoption or derivative · Biotechnology | SEC FORM 4 Code P | —3,073 | filing |
| 31 Aug 2026filed 1 Sep 2026 | QNRX Quoin Pharmaceuticalsoption or derivative · Biotechnology | SEC FORM 4 Code P | —3,073 | filing |
| 31 Aug 2026filed 1 Sep 2026 | QNRX Quoin PharmaceuticalsBiotechnology | SEC FORM 4 Bought | $30K6,146 at $4.88 | filing |
| 27 Aug 2026filed 28 Aug 2026 | QNRX Quoin PharmaceuticalsBiotechnology | SEC FORM 4 Code A | $161K31,352 at $5.15 | filing |
| 27 Aug 2026filed 28 Aug 2026 | QNRX Quoin PharmaceuticalsBiotechnology | SEC FORM 4 Code A | $161K31,352 at $5.15 | filing |
| 4 Feb 2026filed 6 Feb 2026 | QNRX Quoin Pharmaceuticalsoption or derivative · Biotechnology | SEC FORM 4 Code A | —21,709 at $0.00 | filing |
| 4 Feb 2026filed 6 Feb 2026 | QNRX Quoin Pharmaceuticalsoption or derivative · Biotechnology | SEC FORM 4 Code A | —21,709 at $0.00 | filing |
| 21 Aug 2025filed 25 Aug 2025 | QNRX Quoin Pharmaceuticalsoption or derivative · Biotechnology | SEC FORM 4 Code A | —13,682 at $0.00 | filing |
| 29 May 2025filed 3 Jun 2025 | QNRX Quoin Pharmaceuticalsoption or derivative · Biotechnology | SEC FORM 4 Code A | —7,760 at $0.00 | filing |
| 23 Dec 2024filed 27 Dec 2024 | QNRX Quoin Pharmaceuticalsoption or derivative · Biotechnology | SEC FORM 4 Code P | —100,000 | filing |
| 23 Dec 2024filed 27 Dec 2024 | QNRX Quoin Pharmaceuticalsoption or derivative · Biotechnology | SEC FORM 4 Code P | —100,000 | filing |
| 23 Dec 2024filed 27 Dec 2024 | QNRX Quoin PharmaceuticalsBiotechnology | SEC FORM 4 Bought | $45K100,000 at $0.45 | filing |
| 9 Dec 2024filed 10 Dec 2024 | QNRX Quoin Pharmaceuticalsoption or derivative · Biotechnology | SEC FORM 4 Code A | —50,714 at $0.00 | filing |
| 26 Oct 2023filed 30 Oct 2023 | QNRX Quoin Pharmaceuticalsoption or derivative · Biotechnology | SEC FORM 4 Code A | —7,652 at $0.00 | filing |
| 24 Jul 2017filed 26 Jul 2017 | Innocoll Holdings | SEC FORM 4 Code D | —291,566 | filing |
| 24 Jul 2017filed 26 Jul 2017 | Innocoll Holdingsoption or derivative | SEC FORM 4 Code D | —11,659 | filing |
| 24 Jul 2017filed 26 Jul 2017 | Innocoll Holdingsoption or derivative | SEC FORM 4 Code D | —8,230 | filing |
| 24 Jul 2017filed 26 Jul 2017 | Innocoll Holdingsoption or derivative | SEC FORM 4 Code D | —14,907 | filing |
| 24 Jul 2017filed 26 Jul 2017 | Innocoll Holdingsoption or derivative | SEC FORM 4 Code D | —57,240 | filing |
News
Quoin Pharmaceuticals (NASDAQ:QNRX) Stock Rating Raised to "Sell" at Wall Street ZenQNRX · dailypolitical.com · 18 Oct 2026
0 headlines in the last 90 days name Anthony James Culverwell; 1 article from the last 14 days about the 1 company they traded most, at most three about any one of them.